Pasithea Therapeutics (KTTA) Competitors $0.67 -0.03 (-4.86%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. VYNE, PASG, ELEV, RLMD, RLYB, BCAB, CMMB, FNCH, CASI, and ABPShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include VYNE Therapeutics (VYNE), Passage Bio (PASG), Elevation Oncology (ELEV), Relmada Therapeutics (RLMD), Rallybio (RLYB), BioAtla (BCAB), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH), CASI Pharmaceuticals (CASI), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors VYNE Therapeutics Passage Bio Elevation Oncology Relmada Therapeutics Rallybio BioAtla Chemomab Therapeutics Finch Therapeutics Group CASI Pharmaceuticals Abpro Pasithea Therapeutics (NASDAQ:KTTA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer KTTA or VYNE? In the previous week, VYNE Therapeutics had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for VYNE Therapeutics and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.56 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Pasithea Therapeutics Neutral VYNE Therapeutics Negative Which has better valuation & earnings, KTTA or VYNE? Pasithea Therapeutics has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/A-$13.90M-$10.60-0.06VYNE Therapeutics$500K10.86-$39.83M-$0.99-0.36 Do analysts prefer KTTA or VYNE? VYNE Therapeutics has a consensus target price of $6.25, indicating a potential upside of 1,650.70%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VYNE Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, KTTA or VYNE? Pasithea Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Is KTTA or VYNE more profitable? Pasithea Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. VYNE Therapeutics' return on equity of -71.89% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -88.14% -81.21% VYNE Therapeutics -6,974.55%-71.89%-58.94% Do institutionals and insiders believe in KTTA or VYNE? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 2.7% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryVYNE Therapeutics beats Pasithea Therapeutics on 10 of the 14 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.94M$2.98B$5.44B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-0.0618.0530.0425.06Price / SalesN/A175.18373.4277.08Price / CashN/A41.8335.9458.58Price / Book0.067.218.125.67Net Income-$13.90M-$54.43M$3.25B$265.39M7 Day Performance-4.61%0.07%0.96%2.54%1 Month Performance-7.63%5.29%2.69%1.89%1 Year Performance-86.27%9.94%28.08%24.09% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea TherapeuticsN/A$0.67-4.9%N/A-85.3%$4.94MN/A-0.063Upcoming EarningsGap DownVYNEVYNE Therapeutics2.5407 of 5 stars$1.44-0.7%$6.25+334.0%-77.8%$22.05M$500K-1.4530Upcoming EarningsPASGPassage Bio3.3974 of 5 stars$6.34-10.1%$150.00+2,265.9%-65.6%$22MN/A-0.31130News CoverageUpcoming EarningsELEVElevation Oncology2.125 of 5 stars$0.37flat$3.39+827.6%N/A$21.62MN/A-0.4540RLMDRelmada Therapeutics4.605 of 5 stars$0.63-2.3%$5.00+699.5%-81.4%$21.26MN/A-0.2510Earnings ReportRLYBRallybio1.945 of 5 stars$0.47-6.7%$10.00+2,026.8%-57.4%$20.96M$640K-0.4340Gap DownBCABBioAtla1.6127 of 5 stars$0.35-1.8%$5.00+1,338.4%-72.7%$20.68M$11M-0.2860News CoverageCMMBChemomab Therapeutics2.1405 of 5 stars$1.09flat$8.50+679.8%-3.0%$20.55MN/A-1.4320Gap UpFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+288.9%$20.08MN/A-1.42190Gap DownCASICASI Pharmaceuticals4.2479 of 5 stars$1.52-6.2%$4.00+163.2%-76.1%$19.92M$31.37M-0.60180Upcoming EarningsABPAbproN/A$0.32+1.2%$4.00+1,136.9%N/A$19.42M$180K0.0015Positive News Related Companies and Tools Related Companies VYNE Therapeutics Alternatives Passage Bio Alternatives Elevation Oncology Alternatives Relmada Therapeutics Alternatives Rallybio Alternatives BioAtla Alternatives Chemomab Therapeutics Alternatives Finch Therapeutics Group Alternatives CASI Pharmaceuticals Alternatives Abpro Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
